Dr. Stokoe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3705 W 15th St
Plano, TX 75075Phone+1 972-867-3577Fax+1 972-985-9433
Education & Training
- Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2001
- Baylor University Medical CenterResidency, Internal Medicine, 1996 - 1999
- University of Texas Medical Branch School of MedicineClass of 1996
Certifications & Licensure
- TX State Medical License 1997 - 2025
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Publications & Presentations
PubMed
- 5 citationsManagement of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature.Megan L. Kruse, Irene M. Kang, Nusayba Bagegni, W. Todd Howell, Halle C. F. Moore
Oncology and Therapy. 2021-11-20 - 221 citationsNSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by...Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino
Journal of Clinical Oncology. 2020-02-10 - 49 citationsPatients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul
Clinical Cancer Research. 2015-06-03
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: